180 Life Sciences Inc. (NASDAQ: ATNF) stock is rising in the current market by 36.97% after ATNF announced that they have been placed in an editorial published by Networks News Wire due to their research and efforts towards finding the solution for the world’s biggest drivers of disease that is inflammation. 180 Life Sciences is a biotechnology company that deals with the development of therapies for inflammatory diseases, fibrosis, and pain.
The real problem
Inflammation has been associated with a number of physical and mental health conditions. Inflammation is a sign of infectious diseases and has been related to non-infectious diseases. Also according to recent studies inflammation also appears to have a causal association with postsurgical trauma. The most horrifying fact is that inflammation diseases are the leading cause of death in the world with a ratio of 50% death caused by them.
Efforts of 180 Life Sciences towards the solution
180 Life Science was founded by world-renowned scientists who initiated the discovery and creation of one of the first anti-inflammatory therapeutics that came in the market and due to the efficacy of those therapeutics now they make produce several billions of dollars in annual sales. The 180 team is seeking a new anti-inflammatory barnburner with active programs in both preclinical and clinical trials, which is essential to the production of some of the most effective and efficient medicines ever on the market.
Currently, anti-tumor necrosis factor (anti-TNF) antibodies are being researched and tested in autoimmune inflammatory disorders such as rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, ulcerative colitis, and Crohn’s disease, which are expected to increase in the already growth of ATNF in the market.
The key player is that recent research links inflammation to plenty of other diseases with significant unmet medical needs. Clinical trials are currently underway, with more expected for later this year. Market estimates would almost certainly have to be revised significantly higher if ATNF experience any success in their research.